Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683392 · ClinicalTrials.gov registry record · NA
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
A NA study, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT05683392: Completed NA study, sponsored by Tandem Diabetes Care.
NCT05683392 is a NA study that has completed, run by Tandem Diabetes Care. The registered enrollment target is 72 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05683392, a NA study, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.
Primary Outcome
Number of severe hypoglycemic events (with cognitive impairment such that assistance of another individual is needed for treatment) during study compared with data on severe hypoglycemic events reported by T1D Exchange clinic registry over a 3-month time period
Interventions
- DEVICE t:slim X2 insulin pump with Control-IQ technology 2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2023-12-13 |
| Phase | NA |
What the finished NCT05683392 record still lists
NCT05683392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which t:slim X2 insulin pump with Control-IQ technology 2.0 is the first listed.
NCT05683392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05683392 about?
NCT05683392 is a clinical study titled "Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes". The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.
What is the current status of trial NCT05683392?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2023-02-01. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT05683392?
The interventions under investigation include: t:slim X2 insulin pump with Control-IQ technology 2.0 (DEVICE).
Who is sponsoring clinical trial NCT05683392?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05683392's enrollment target sits among peer trials
72 1089th of 2000 higher than 899 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI